Tom O’Shea, PhD
Vice President of Preclinical Development
Dr. O’Shea joined Cyteir as Head of Preclinical Development in October 2018. He brings to Cyteir over 25 years of R&D experience in the pharmaceutical industry with a proven track record of successfully supporting preclinical research and development across diverse therapeutic areas. Dr. O’Shea is an expert in drug metabolism and pharmacokinetics (DMPK).
Prior to joining Cyteir, Dr. O’Shea was the US Head of DMPK in Sanofi and Vice President of DMPK and Pharmaceutics in Genzyme. In these roles, he contributed to the successful global registration of several drugs including Mozobil, Kynamro and Cerdelga. Dr O’Shea has also supported numerous investigational new drug applications and is a co-inventor of venglustat currently in clinical development for the treatment of multiple indications caused by lysosomal dysfunction. Dr. O’Shea began his pharmaceutical career in Searle where he held roles of increasing responsibility through a merger with Pharmacia & UpJohn and the subsequent acquisition by Pfizer. Following a role in AstraZeneca, Dr. O’Shea joined Genzyme in 2005 to establish the DMPK organization.
Dr. O’Shea earned a BSc in Analytical Science and a PhD in Chemistry from Dublin City University.